Owlet Smart Sock (Discontinued): Should You Buy One in 2026?

What the Owlet Smart Sock was

The Owlet Smart Sock launched in 2015 and was the product that created the consumer infant-vitals category. A small fabric sock with an embedded sensor wrapped around the baby's foot and reported pulse rate and blood oxygen (SpO2) to a base station, which then forwarded readings to the parent's phone via the Owlet app.

Three generations shipped — Smart Sock, Smart Sock 2, Smart Sock 3 — each refining battery life, fit, and the base station. At its peak, Owlet was the default answer to 'how do I track my baby's vitals?' and built a strong brand among first-time parents in the US.

Owlet always carried a 'not a medical device' disclaimer in its T&Cs, but its marketing — particularly around alerts when readings dropped — leaned heavily on language that parents reasonably interpreted as health monitoring. That gap between disclaimer and marketing is what eventually drew the FDA's attention.

Why the FDA pulled it

On October 5, 2021, the FDA issued Warning Letter CBER 616354 to Owlet Baby Care, Inc. The letter's core finding: by alerting parents to specific SpO2 and pulse-rate thresholds tied to medical conditions like hypoxemia and bradycardia, the Smart Sock met the statutory definition of a medical device under the Federal Food, Drug, and Cosmetic Act — and was being marketed without the required premarket clearance or approval.

Importantly, the FDA did not allege any safety incident. There was no recall in the conventional sense — no injuries, no deaths attributed to the device, no manufacturing defect. The action was a regulatory classification dispute: the FDA said 'this is a medical device,' Owlet had been operating as if it weren't, and the device couldn't keep being sold in that posture.

Owlet pulled the Smart Sock from US sale shortly after receiving the letter. Smart Sock 3 lingered in some international markets — UK retailer MORI carried it, Amazon UK listed it around £299 — but Owlet's strategy pivoted to building a successor that could meet FDA requirements head-on.

What the Dream Sock changed

On November 8, 2023, the FDA granted De Novo clearance to the Owlet Dream Sock under request DEN220091. De Novo is the FDA's pathway for novel low-to-moderate-risk devices that don't have a predicate; Dream Sock became Class II, and Owlet became the first consumer baby-vitals brand with an FDA-cleared product.

Mechanically, the Dream Sock measures the same things — pulse rate and SpO2 — but ships with a tighter intended-use statement and clinically-validated alert thresholds. It also adds sleep tracking on top of vitals, which is the first-time-parent feature that turned the relaunch into a real upgrade and not just a regulatory rename.

Owlet now sells Dream Sock as the flagship in both the US and UK. Smart Sock 3 is being phased out internationally as Dream Sock takes over distribution.

Should you buy a used or international Smart Sock today?

Practical answer: probably not. The hardware itself can still pair and report readings, but you're buying a product that is no longer supported in its launch market, that was specifically called out by the FDA for its alert behavior, and that Owlet itself is steering customers away from. Firmware updates, app compatibility, and replacement parts will all decay over time.

The international Smart Sock 3 stock you'll find on eBay or marketplace listings is a similar story — it works today, but it's a sunset product. Spending Smart Sock money to get Smart Sock features, when Dream Sock exists for similar money and is FDA cleared, is a hard recommendation to make.

If you're dead set on the Smart Sock specifically — for example, you already own a base station and want a backup sock — that's a defensible niche use. For a fresh purchase as a first sock for a new baby, buy Dream Sock instead.

What to buy instead

Two paths, depending on what you actually want:

If you want FDA-cleared pulse-rate and oxygen tracking on a wearable — the original Smart Sock's value proposition — the answer is the Owlet Dream Sock. It's the same sensor concept with the regulatory clearance the original lacked, plus sleep tracking. There is no other FDA-cleared consumer infant pulse-ox product on the market today.

If you want video, two-way talk, AI scene understanding, and offline monitoring — a totally different product category from a vitals sock — Tuck is one option. Tuck turns two iPhones into a real-time monitor with personalized AI lullabies and works without Wi-Fi via custom Bluetooth Coded PHY. Tuck does not measure heart rate or oxygen and is explicitly not a medical device. Many families end up with both a vitals sock and a video monitor; they're complementary, not interchangeable.

If you want a contactless wearable alternative to a sock, Sense-U makes a clip-on belly band with breathing-motion and temperature sensors. It is also not FDA cleared. There is no contactless FDA-cleared option in the consumer category as of 2026.

What this episode taught the category

The Smart Sock saga is the cleanest case study in consumer baby-tech of the gap between 'wellness device' marketing and 'medical device' regulatory reality. Every brand selling vitals tracking now writes its marketing copy with that 2021 letter in mind.

It also reset reasonable expectations about what video baby monitors should claim. No video monitor on the market today is FDA cleared — and any brand that implies otherwise is overreaching. Tuck's own positioning is explicit on this: 'not a medical device, not a substitute for adult supervision.' Nanit and Cubo Ai are similarly careful in their current copy, in part because the Owlet outcome made clear what happens when you aren't.

If there's a takeaway for parents shopping in 2026: a vitals sock and a video monitor are different tools for different jobs. Buy the FDA-cleared option for vitals, buy the option that fits your home and travel patterns for video, and don't buy a discontinued product because the search results are stale.

Frequently asked questions